Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 277

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 277
---
 in Note 3.

5

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 

(in thousands)

(unaudited)

Nine Months Ended September 30,20252024Cash flows from operating activitiesNet loss$(46,231)$(37,117)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization180 33 Loss on impairment of operating right-of-use assets and related property and equipment82 — Accretion of discounts on marketable securities(2,801)(2,593)Change in fair value of preferred stock warrants— 1,047 Share-based compensation expense8,869 4,735 Changes in operating assets and liabilities:Inventory(949)— Prepaid expenses and other current assets(1,103)(684)Accounts payable66 (5,599)Accrued liabilities5,946 (8,758)Other assets(204)(1,377)Net cash used in operating activities(36,145)(50,313)Cash flows from investing activitiesPurchases of marketable securities(147,691)(195,297)Proceeds from maturities of marketable securities162,622 53,000 Purchases of property and equipment(789)(319)Net cash provided by (used in) investing activities14,142 (142,616)Cash flows from financing activitiesProceeds from issuance of common stock through at-the-market offerings, net of issuance costs26,067 — Proceeds from exercises of stock options838 3,900 Proceeds from issuance of common stock under employee stock purchase plan225 — Cash, cash equivalents, and restricted cash acquired in connection with the Merger— 117,824 Proceeds from issuance of common stock, net of issuance costs— 79,598 Merger transaction costs— (2,373)Net cash provided by financing activities27,130 198,949 Net increase in cash, cash equivalents, and restricted cash5,127 6,020 Cash and cash equivalents, and restricted cash, beginning of the period20,272 35,140 Cash, cash equivalents, and restricted cash, end of the period$25,399 $41,160 Supplemental cash flow informationConversion of Series A, A-1, and B convertible preferred stock to common stock$— $137,490 Conversion of Class B convertible